KR20180094989A - 노화 관련 인지장애 및 신경염증의 예방 및/또는 치료 방법 - Google Patents

노화 관련 인지장애 및 신경염증의 예방 및/또는 치료 방법 Download PDF

Info

Publication number
KR20180094989A
KR20180094989A KR1020187020017A KR20187020017A KR20180094989A KR 20180094989 A KR20180094989 A KR 20180094989A KR 1020187020017 A KR1020187020017 A KR 1020187020017A KR 20187020017 A KR20187020017 A KR 20187020017A KR 20180094989 A KR20180094989 A KR 20180094989A
Authority
KR
South Korea
Prior art keywords
aging
animals
subject
zln005
neuroinflammation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020187020017A
Other languages
English (en)
Korean (ko)
Inventor
코아 딘 느구옌
에드가 지. 엥글레만
Original Assignee
더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 주니어 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 주니어 유니버시티 filed Critical 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 주니어 유니버시티
Publication of KR20180094989A publication Critical patent/KR20180094989A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Hydrogenated Pyridines (AREA)
KR1020187020017A 2015-12-15 2016-12-09 노화 관련 인지장애 및 신경염증의 예방 및/또는 치료 방법 Ceased KR20180094989A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562267437P 2015-12-15 2015-12-15
US62/267,437 2015-12-15
PCT/US2016/065972 WO2017106050A1 (en) 2015-12-15 2016-12-09 Method for preventing and/or treating aging-associated cognitive impairment and neuroinflammation

Publications (1)

Publication Number Publication Date
KR20180094989A true KR20180094989A (ko) 2018-08-24

Family

ID=59057428

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187020017A Ceased KR20180094989A (ko) 2015-12-15 2016-12-09 노화 관련 인지장애 및 신경염증의 예방 및/또는 치료 방법

Country Status (18)

Country Link
US (3) US10653669B2 (enExample)
EP (2) EP3390367B1 (enExample)
JP (1) JP6837486B2 (enExample)
KR (1) KR20180094989A (enExample)
CN (1) CN108884053B (enExample)
AU (1) AU2016371598B2 (enExample)
CA (1) CA3008019A1 (enExample)
DK (1) DK3390367T3 (enExample)
ES (1) ES2830447T3 (enExample)
HR (1) HRP20201652T1 (enExample)
HU (1) HUE051771T2 (enExample)
IL (2) IL285248B2 (enExample)
MX (1) MX379086B (enExample)
PL (1) PL3390367T3 (enExample)
PT (1) PT3390367T (enExample)
RS (1) RS61053B1 (enExample)
SM (1) SMT202000601T1 (enExample)
WO (1) WO2017106050A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016061190A1 (en) 2014-10-14 2016-04-21 The Board Of Trustees Of The Leland Stanford Junior University Method for treating neurodegenerative diseases
ES2830447T3 (es) * 2015-12-15 2021-06-03 Univ Leland Stanford Junior Método para la prevención y/o el tratamiento del deterioro cognitivo asociado al envejecimiento y la neuroinflamación
BR112021002165A2 (pt) * 2018-08-06 2021-05-04 The Board Of Trustees Of The Leland Stanford Junior University composto, composição farmacêutica, e, métodos para tratar uma doença neurodegenerativa e deficiência cognitiva associada ao envelhecimento e neuroinflamação
US20240316008A1 (en) 2020-06-22 2024-09-26 Tranquis Therapeutics, Inc. Treatment of systemic immune activation syndromes
CN112933232A (zh) * 2021-02-02 2021-06-11 袁玉佳 PGC-1α激活TFEB介导的自噬在制备治疗急性肾损伤的药物中的应用
CN117794531A (zh) * 2021-06-17 2024-03-29 特朗奎斯治疗股份有限公司 2-芳基苯并咪唑的治疗上有效的口服给药
EP4355326A4 (en) * 2021-06-17 2025-04-23 Tranquis Therapeutics, Inc. THERAPEUTICALLY EFFECTIVE ORAL ADMINISTRATION OF A 2-ARYL-BENZIMIDAZOLE
CN118541152A (zh) 2021-11-02 2024-08-23 特朗奎斯治疗股份有限公司 具有循环髓样细胞炎性表型的受试者的选择和治疗
TW202415372A (zh) 2022-06-14 2024-04-16 美商特朗奎斯治療股份有限公司 老化相關改變及疾病之治療
TW202416960A (zh) 2022-06-17 2024-05-01 美商特朗奎斯治療股份有限公司 2-芳基苯并咪唑化合物之調配物
CN120752039A (zh) * 2022-11-18 2025-10-03 五条聪 Zln-005和相关化合物的用途
US20260199293A1 (en) 2022-12-02 2026-07-16 Tranquis Therapeutics, Inc. 2-Arylbenzimidazole Compounds for the Treatment of Hemoglobinopathies

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL275435A (enExample) 1961-03-01
US4038396A (en) 1975-02-24 1977-07-26 Merck & Co., Inc. Anti-inflammatory oxazole[4,5-b]pyridines
GB1584296A (en) 1976-12-07 1981-02-11 Kanebo Ltd 2-substituted benzimidazole compounds
JPS53127475A (en) * 1977-04-07 1978-11-07 Kanebo Ltd Novel benzimidazole compound and its preparation
NZ234564A (en) 1986-11-21 1991-04-26 Haessle Ab 1-substituted benzimidazoles and pharmaceutical compositions
DE3830060A1 (de) 1988-09-03 1990-03-15 Boehringer Mannheim Gmbh 2-phenylbenzimidazole - verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel
US5552426A (en) 1994-04-29 1996-09-03 Eli Lilly And Company Methods for treating a physiological disorder associated with β-amyloid peptide
TR200101239T2 (tr) 1998-11-03 2001-11-21 Basf Aktiengesellschaft İkameli-2-fenilbenzimidazoller, üretimleri ve kullanımları
IL150150A0 (en) * 2000-01-14 2002-12-01 Schering Ag 1,2-diaryl benzimidazoles for treating illnesses associated with a microglia activation
DE10134775A1 (de) * 2001-07-06 2003-01-30 Schering Ag 1-Alkyl-2.aryl-benzimidazolderivate, deren Verwendung zur Herstellung von Arzneimitteln sowie diese Derivate enthaltende pharmazeutische Präparate
DE10207843A1 (de) * 2002-02-15 2003-09-04 Schering Ag Mikrolia-Inhibitoren zur Unterbrechung von Interleukin 12 und IFN-gamma vermittelten Immunreaktionen
US20040002524A1 (en) * 2002-06-24 2004-01-01 Richard Chesworth Benzimidazole compounds and their use as estrogen agonists/antagonists
US20040147581A1 (en) 2002-11-18 2004-07-29 Pharmacia Corporation Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
WO2004093802A2 (en) 2003-04-17 2004-11-04 The Board Of Trustees Of The Leland Stanford Junior University Prevention of deficits in neurogenesis with anti-inflammatory agents
SE0301371D0 (sv) 2003-05-09 2003-05-09 Astrazeneca Ab New Compounds
WO2005112913A1 (en) 2004-05-20 2005-12-01 The Scripps Research Institute Transthyretin stabilization
BRPI0512239A (pt) * 2004-06-17 2008-02-19 Wyeth Corp processos para preparação de antagonistas de receptores de hormÈnios liberadores de gonatropina
KR20070057965A (ko) * 2004-09-21 2007-06-07 신타 파마슈티칼스 코프. 염증 및 면역 관련 용도를 위한 화합물
US7689227B2 (en) * 2005-03-02 2010-03-30 Qualcomm Incorporated Method and apparatus for hashing over multiple frequency bands in a communication system
US20060223849A1 (en) * 2005-03-14 2006-10-05 Mjalli Adnan M Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors
CA2616512A1 (en) 2005-07-28 2007-02-08 Intervet International B.V. Novel benzimidazole (thio) carbamates with antiparasitic activity and the synthesis thereof
US7345178B2 (en) 2005-08-04 2008-03-18 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
WO2008059026A1 (en) 2006-11-15 2008-05-22 High Point Pharmaceuticals, Llc Novel 2-(2-hydroxyphenyl)benzimidazoles useful for treating obesity and diabetes
GB0807103D0 (en) 2008-04-18 2008-05-21 Univ Bradford The Compounds
US8835648B2 (en) 2009-06-11 2014-09-16 Siena Biotech S.P.A. Hedgehog pathway antagonists and therapeutic applications thereof
MX2012005248A (es) 2009-11-06 2012-06-14 Univ Vanderbilt Aril- y heteroaril-sulfonas como potenciadores alostericos de mglur4, composiciones y metodos de tratamiento de la disfuncion neurologica.
WO2016187217A2 (en) * 2015-05-18 2016-11-24 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating aging-associated impairments
GB201009656D0 (en) 2010-06-09 2010-07-21 Univ St Andrews Carboxylation catalysts
CN104662018B (zh) 2012-04-20 2017-10-24 阿迪维纳斯治疗有限公司 取代的杂双环化合物、组合物及其医疗应用
WO2014037340A1 (de) 2012-09-05 2014-03-13 Bayer Cropscience Ag Verwendung substituierter 2-amidobenzimidazole, 2-amidobenzoxazole und 2-amidobenzothiazole oder deren salze als wirkstoffe gegen abiotischen pflanzenstress
KR101435496B1 (ko) 2012-10-22 2014-08-28 한국과학기술연구원 미토콘드리아 기능 조절제로서의 벤즈이미다졸 유도체
US10022357B2 (en) 2013-04-29 2018-07-17 The General Hospital Corporation Amyloid precursor protein MRNA blockers for treating Down syndrome and Alzheimer's disease
ES2830352T3 (es) * 2013-09-18 2021-06-03 Univ Georgetown Tratamiento de enfermedad neurodegenerativa con fenofibrato y análogos del mismo
WO2016061190A1 (en) 2014-10-14 2016-04-21 The Board Of Trustees Of The Leland Stanford Junior University Method for treating neurodegenerative diseases
CN104873500A (zh) 2015-04-29 2015-09-02 中国人民解放军第四军医大学 化合物zln005的用途
ES2830447T3 (es) * 2015-12-15 2021-06-03 Univ Leland Stanford Junior Método para la prevención y/o el tratamiento del deterioro cognitivo asociado al envejecimiento y la neuroinflamación
JP2018083799A (ja) 2016-11-15 2018-05-31 バイオエレクトロン テクノロジー コーポレイション ２−置換アミノ−ナフト［１，２−ｄ］イミダゾール−５−オン化合物またはその製薬学上許容される塩
BR112021002165A2 (pt) 2018-08-06 2021-05-04 The Board Of Trustees Of The Leland Stanford Junior University composto, composição farmacêutica, e, métodos para tratar uma doença neurodegenerativa e deficiência cognitiva associada ao envelhecimento e neuroinflamação
US20240316008A1 (en) * 2020-06-22 2024-09-26 Tranquis Therapeutics, Inc. Treatment of systemic immune activation syndromes

Also Published As

Publication number Publication date
IL259902A (en) 2018-07-31
ES2830447T3 (es) 2021-06-03
BR112018012195A2 (pt) 2018-12-18
CA3008019A1 (en) 2017-06-22
HRP20201652T1 (hr) 2020-12-25
JP6837486B2 (ja) 2021-03-03
IL285248B2 (en) 2025-10-01
MX379086B (es) 2025-03-10
EP3390367A1 (en) 2018-10-24
EP3741747B1 (en) 2024-10-16
CN108884053A (zh) 2018-11-23
IL285248A (en) 2021-09-30
WO2017106050A1 (en) 2017-06-22
AU2016371598B2 (en) 2021-05-13
RS61053B1 (sr) 2020-12-31
HUE051771T2 (hu) 2021-03-29
HK1261918A1 (en) 2020-01-10
US20180353474A1 (en) 2018-12-13
MX2018007147A (es) 2019-03-28
IL285248B1 (en) 2025-06-01
CN108884053B (zh) 2022-01-04
EP3741747C0 (en) 2024-10-16
US10653669B2 (en) 2020-05-19
AU2016371598A1 (en) 2018-07-12
EP3390367B1 (en) 2020-09-09
US12678424B2 (en) 2026-07-14
US20240245646A1 (en) 2024-07-25
JP2018537507A (ja) 2018-12-20
IL259902B (en) 2021-08-31
EP3741747A1 (en) 2020-11-25
DK3390367T3 (da) 2020-10-26
SMT202000601T1 (it) 2021-01-05
EP3390367A4 (en) 2019-08-07
PL3390367T3 (pl) 2021-03-08
PT3390367T (pt) 2020-09-23
US20210059985A1 (en) 2021-03-04

Similar Documents

Publication Publication Date Title
US20240245646A1 (en) Method for preventing and/or treating aging-associated cognitive impairment and neuroinflammation
TWI870475B (zh) 用於治療神經毒性之方法及材料
KR20250083233A (ko) 화농성 한선염 치료를 위한 방법 및 조성물
JP2017128578A (ja) 腎疾患の治療におけるモノおよびジカルボン酸のアミドの使用
JP6185575B2 (ja) 皮膚炎症性疾患の治療方法
ES2702578T3 (es) Tratamiento de la inflamación dérmica crónica con norketotifeno
US10548870B2 (en) Method for treating multiple sclerosis
US20200170990A1 (en) Method for treating schnitzler's syndrome
WO2018151285A1 (ja) 掻痒性皮膚疾患の予防又は治療薬
HK40041872A (en) Method for preventing and/or treating aging-associated cognitive impairment
US10438128B2 (en) Treatment of autoimmune and inflammatory diseases with the arsenic compounds AS2O3 and/or AS2O5 administered locally
HK1261918B (en) Method for preventing and/or treating aging-associated cognitive impairment and neuroinflammation
KR102619489B1 (ko) 폴마콕시브 및 트라마돌을 포함하는 급, 만성 통증 치료용 약제학적 조성물
BR112018012195B1 (pt) Uso de 2-[4-(1,1-dimetiletil)fenil]-1h-benzimidazol, ou um sal farmaceuticamente aceitável do mesmo
US9284281B2 (en) Indication of naphtho[2,3-F]quinoxaline-7,12-dione compound in alleviating pain
HK1086500A (en) Use of a topical medicament comprising riluzole
TW201817426A (zh) 三萜混合物用以治療多發性硬化的用途

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601